10 Stocks Under $10 that Will Triple

1. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Upside Potential: 421.89%

Number Of Hedge Funds: 45

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotech company focusing on the development of gene therapies for rare and fatal diseases. The company’s solutions include ex vivo lentiviral vector treatments for Fanconi anemia, leukocyte adhesion deficiency-I, and pyruvate kinase deficiency. The company is also making progress in vivo AAV therapies that target Danon disease, plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM), and BAG3 dilated cardiomyopathy.

As of December 31, 2024, Rocket Pharmaceuticals (NASDAQ:RCKT) had $372.3 million in cash, substantial enough to sustain the company till Q3 2026. On the other hand, R&D costs fell to $171.2 million in 2024 from  $186.3 million in 2023 due to lower manufacturing and development expenses. However, G&A costs rose to $102 million to prepare for commercialization. Although Rocket posted a net loss of $258.7 million, slightly worse than the previous year, it raised $182.5 million. This was through a public offering in December 2024, bolstering the company’s reserves for ongoing clinical work.

Moreover, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has made critical clinical strides, especially with RP-A501 for Danon disease. The New England Journal of Medicine published its long-term data, highlighting the treatment’s lasting effect. The Phase 2 pivotal study continues, with updates expected to come by the first half of 2025. In addition, Rocket also finished enrolling patients in its Phase 1 trial for PKP2-ACM, with initial results expected this year. Its regulatory reviews are moving forward for KRESLADI (LAD-I) and RP-L102 (Fanconi anemia), setting the company up for approvals soon.

Thus, Rocket Pharmaceuticals (NASDAQ:RCKT) demonstrates a strong upside potential with its advanced gene therapies, targeting rare diseases that have few treatment options. Positive trial outcomes, regulatory approvals, and commercialization could significantly boost its value, making it one of the $10 stocks that will triple.

Overall, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ranks first on our list of the 10 Stocks Under $10 that Will Triple. While we acknowledge the potential of RCKT, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RCKT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.